/PRNewswire/ Congruence Therapeutics, a leading computationally-driven biotechnology company developing a pipeline of novel small molecules for diseases.
/PRNewswire/ Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors.
/PRNewswire/ Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel.
MONTREAL, Sept. 6, 2023 /CNW/ Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecule correctors for diseases of
Ipsen s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients .